Nitin and colleagues investigated the efficacy of a mixture of immune-peptides in ten CML patients expressing e13a2 or co-expressing e13a2/e14a2 BCR-ABL1 isoforms. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.